All In Biotech

Drug Trial Radar · NCT00268697

Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.

A Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg and Lapaquistat Acetate 100 mg Administered in Combination With Ezetimibe 10 mg vs Ezetimibe 10 mg in Subjects With Primary Dyslipidemia

Last checked: Nov 19, 2026Latest source record: May 24, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,267 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,267

Actual

Start

Oct 2005

Primary completion

Jan 2007

Study completion Jan 2007

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Dec 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with ezetimibe on cholesterol levels in subjects with primary dyslipidemia

Conditions

  • Hypercholesterolemia

Interventions

  • Lapaquistat acetateDrug

    Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.

  • Lapaquistat acetate and ezetimibeDrug

    Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.

  • EzetimibeDrug

    Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in fasting plasma Low Density Lipoprotein cholesterolTime frame: Week 24 or Final Visit

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Tallinn, Estonia

  • Site not named

    Tartu, Estonia

  • Site not named

    Riga, Latvia

  • Site not named

    Moscow, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saratov, Russia

  • Site not named

    Smolensk, Russia

  • Site not named

    Tyumen, Russia

  • Site not named

    Kragujevac, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.